eFFECTOR Therapeutics Regains Nasdaq Compliance Status

eFFECTOR Therapeutics (EFTR) has released an update.

eFFECTOR Therapeutics, Inc. has received confirmation from Nasdaq that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. This follows a prior notification of non-compliance due to the company’s stock failing to meet the minimum bid price over a 30-day period. With this issue resolved, the matter is now considered closed by Nasdaq.

For further insights into EFTR stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.